TAK 058

Drug Profile

TAK 058

Alternative Names: ENV-8058

Latest Information Update: 09 Nov 2016

Price : $50

At a glance

  • Originator Envoy Therapeutics
  • Developer Takeda
  • Class Antidementias; Antipsychotics
  • Mechanism of Action Serotonin 3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Schizophrenia

Most Recent Events

  • 01 Dec 2015 Phase-I clinical trials in Schizophrenia (Combination therapy) in USA (PO)
  • 01 Dec 2015 Takeda completes a phase I trial in Healthy volunteers in USA (NCT02389881)
  • 28 Nov 2015 Takeda plans a phase I trial in Schizophrenia (Combination therapy) in USA (NCT02614586)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top